Schonfeld Strategic Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-108,400
Closed -$10.7M 2446
2024
Q3
$10.7M Buy
+108,400
New +$10.7M 0.07% 283
2024
Q1
Sell
-100,000
Closed -$8.93M 2457
2023
Q4
$8.93M Sell
100,000
-301,000
-75% -$22.4M 0.06% 384
2023
Q3
$29.3M Sell
401,000
-150,000
-27% -$12M 0.23% 105
2023
Q2
$2.1M Buy
+551,000
New +$46.1M 0.02% 738
2020
Q4
Sell
-150,000
Closed -$16.7M 1916
2020
Q3
$16.7M Buy
+150,000
New +$16.8M 0.32% 63

Other funds holding XBI

Schonfeld Strategic Advisors's XBI Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 7,643 shares worth $976K. The stake represents 0.01% of the portfolio and ranks #1107 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in XBI as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in XBI in Q3 2020 and has held it in 19 quarters since. The position peaked at $31M in Q2 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Schonfeld Strategic Advisors held 7,643 shares of State Street SPDR S&P Biotech ETF worth $976K as of Q1 2026.
  • State Street SPDR S&P Biotech ETF was a new Schonfeld Strategic Advisors position in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1107 holding.
  • Schonfeld Strategic Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 19 quarters since.
  • Schonfeld Strategic Advisors's State Street SPDR S&P Biotech ETF position peaked at $31M in Q2 2023.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.